Nikolaos Dimisianos
Nikolaos Dimisianos has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Dimitra Kalavrizioti
Division of Hematology, Department of Internal Medicine, University of Patras Medical School , Rion 265 00
2 shared publications Panagiotis Papathanasopoulos
2 shared publicationsAthanasia Mouzaki
Division of Hematology, Department of Internal Medicine, Medical School, University of Patras, 26500 Patras, Greece
1 shared publication- Athanasia Mouzaki
Laboratory of Immunohematology, Medical School, University of Patras, Patras, Greece
1 shared publication - Davina Camargo Madeira Simoes
Faculty of Science and Environment, Northumbria University, Newcastle upon Tyne NE1 8ST, UK
1 shared publication Elisavet Tselengidou
1 shared publication
Latest Publications
- Open Access
- 1 October 2016
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 197 (7) , 2598-2609
ERβ-Dependent Direct Suppression of Human and Murine Th17 Cells and Treatment of Established Central Nervous System Autoimmunity by a Neurosteroid
Multiple sclerosis (MS), an autoimmune disease of the CNS, is mediated by autoreactive Th cells. A previous study showed that the neurosteroid dehydroepiandrosterone (DHEA), when administered preclinically, could suppress progression of relapsing-remitting experimental autoimmune encephalomyelitis (EAE). However, the effects of DHEA on human or murine pathogenic immune cells, such as Th17, were unknown. In addition, effects of this neurosteroid on symptomatic disease, as well as the receptors involved, had not been investigated. In this study, we show that DHEA suppressed peripheral responses from patients with MS and reversed established paralysis and CNS inflammation in four different EAE models, including the 2D2 TCR-transgenic mouse model. DHEA directly inhibited human and murine Th17 cells, inducing IL-10–producing regulatory T cells. Administration of DHEA in symptomatic mice induced regulatory CD4+ T cells that were suppressive in an IL-10–dependent manner. Expression of the estrogen receptor β by CD4+ T cells was necessary for DHEA-mediated EAE amelioration, as well as for direct downregulation of Th17 responses. TGF-β1 as well as aryl hydrocarbon receptor activation was necessary for the expansion of IL-10–producing T cells by DHEA. Thus, our studies demonstrate that compounds that inhibit pathogenic Th17 responses and expand functional regulatory cells could serve as therapeutic agents for autoimmune diseases, such as MS.
- 1 October 2016
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 197 (7) , 2598-2609
Open AccessERβ-Dependent Direct Suppression of Human and Murine Th17 Cells and Treatment of Established Central Nervous System Autoimmunity by a Neurosteroid
Multiple sclerosis (MS), an autoimmune disease of the CNS, is mediated by autoreactive Th cells. A previous study showed that the neurosteroid dehydroepiandrosterone (DHEA), when administered preclinically, could suppress progression of relapsing-remitting experimental autoimmune encephalomyelitis (EAE). However, the effects of DHEA on human or murine pathogenic immune cells, such as Th17, were unknown. In addition, effects of this neurosteroid on symptomatic disease, as well as the receptors involved, had not been investigated. In this study, we show that DHEA suppressed peripheral responses from patients with MS and reversed established paralysis and CNS inflammation in four different EAE models, including the 2D2 TCR-transgenic mouse model. DHEA directly inhibited human and murine Th17 cells, inducing IL-10–producing regulatory T cells. Administration of DHEA in symptomatic mice induced regulatory CD4+ T cells that were suppressive in an IL-10–dependent manner. Expression of the estrogen receptor β by CD4+ T cells was necessary for DHEA-mediated EAE amelioration, as well as for direct downregulation of Th17 responses. TGF-β1 as well as aryl hydrocarbon receptor activation was necessary for the expansion of IL-10–producing T cells by DHEA. Thus, our studies demonstrate that compounds that inhibit pathogenic Th17 responses and expand functional regulatory cells could serve as therapeutic agents for autoimmune diseases, such as MS.
- 1 January 2015
- Published by Wolters Kluwer Health in The Neurologist
- Vol. 19 (2) , 38-39
Trigeminal Herpes Zoster Complicated By Ramsay Hunt Syndrome
We report the case of a 55-year-old woman with herpes zoster of the mandibular branch of the left trigeminal nerve, which was complicated within 4 days by ipsilateral Ramsay Hunt syndrome. Recently, a case of trigeminal herpes zoster and Ramsay Hunt syndrome was described, in which the MRI and CSF findings along with the clinical course urged the authors to suggest the possibility of transaxonal spread of the virus. In our case, the findings and particularly the temporal relation between the 2 conditions render more plausible other pathophysiological mechanisms, such as the spread of the virus through the CSF.
- 1 January 2015
- Published by Wolters Kluwer Health in The Neurologist
- Vol. 19 (2) , 38-39
Trigeminal Herpes Zoster Complicated By Ramsay Hunt Syndrome
We report the case of a 55-year-old woman with herpes zoster of the mandibular branch of the left trigeminal nerve, which was complicated within 4 days by ipsilateral Ramsay Hunt syndrome. Recently, a case of trigeminal herpes zoster and Ramsay Hunt syndrome was described, in which the MRI and CSF findings along with the clinical course urged the authors to suggest the possibility of transaxonal spread of the virus. In our case, the findings and particularly the temporal relation between the 2 conditions render more plausible other pathophysiological mechanisms, such as the spread of the virus through the CSF.
- Open Access
- 22 July 2014
- Published by Wiley in Multiple Sclerosis International
- Vol. 2014, 1-8
Cytokines as Biomarkers of Treatment Response to IFNβin Relapsing-Remitting Multiple Sclerosis
Background. MS patients show a remarkable heterogeneity in their response to disease modifying treatments. Given the need for early treatment initiation and the diversity of available options, a predictive marker that indicates good or poor response to treatment is highly desirable.Objective. To find a biomarker for treatment response to IFNβamong pro- and anti-inflammatory cytokines.Materials and Methods. IFN-γ, TNF-α, IL-2, IL-4, IL-6, IL-10, IL-17A, and TGF-β1 levels were measured in serum and CSF of 43 patients with RR-MS who were followed up for a mean period of 5.3 years. Thirty-five patients received IFNβtreatment and were divided into good responders (GR,n= 19) and poor responders (PR,n= 16). The remaining 8 patients showed a very favorable outcome and remained untreated (noRx).Results. GR had significantly higher serum baseline levels of IL-17A than PR and significantly higher serum levels of IL-17A, IFN-γ, TNF-α, and IL-2 than noRx. PR had significantly higher IFN-γserum levels than noRx. No significant differences were observed in serum levels of IL-6, IL-4, IL-10, and TGF-β1 or the levels of all cytokines measured in CSF between the 3 groups of patients.Conclusions. Baseline serum levels of IL-17A can be used as a biomarker of IFNβtreatment response.
- 22 July 2014
- Published by Wiley in Multiple Sclerosis International
- Vol. 2014, 1-8
Open AccessCytokines as Biomarkers of Treatment Response to IFNβin Relapsing-Remitting Multiple Sclerosis
Background. MS patients show a remarkable heterogeneity in their response to disease modifying treatments. Given the need for early treatment initiation and the diversity of available options, a predictive marker that indicates good or poor response to treatment is highly desirable.Objective. To find a biomarker for treatment response to IFNβamong pro- and anti-inflammatory cytokines.Materials and Methods. IFN-γ, TNF-α, IL-2, IL-4, IL-6, IL-10, IL-17A, and TGF-β1 levels were measured in serum and CSF of 43 patients with RR-MS who were followed up for a mean period of 5.3 years. Thirty-five patients received IFNβtreatment and were divided into good responders (GR,n= 19) and poor responders (PR,n= 16). The remaining 8 patients showed a very favorable outcome and remained untreated (noRx).Results. GR had significantly higher serum baseline levels of IL-17A than PR and significantly higher serum levels of IL-17A, IFN-γ, TNF-α, and IL-2 than noRx. PR had significantly higher IFN-γserum levels than noRx. No significant differences were observed in serum levels of IL-6, IL-4, IL-10, and TGF-β1 or the levels of all cytokines measured in CSF between the 3 groups of patients.Conclusions. Baseline serum levels of IL-17A can be used as a biomarker of IFNβtreatment response.